Denali’s Sanofi-partnered RIPK1 inhibitorRIPK1 inhibitor fails ALS study
2024-02-16
临床2期并购
Denali Therapeutics reported in a securities filing Friday that its experimental amyotrophic lateral sclerosis (ALS) treatment missed the primary endpoint in a Phase II study run by partner Sanofi. Shares in the biotech slipped 7% on the news, which isn’t the first setback the collaborators have faced.
The RIPK1 inhibitorRIPK1 inhibitor – known as either DNL788 or SAR443820 – missed the primary endpoint of change in ALS Functional Rating Scale-Revised (ALSFRS-R) in the 305-person Phase II HIMALAYA study. Denali said the results will not impact the Phase II K2 study in multiple sclerosis, for which Sanofi recently finished enrolling 174 patients.
Sanofi and Denali partnered in 2018 to develop a pair of RIPK1 inhibitorsRIPK1 inhibitors against a range of neurological and systemic inflammatory diseases. The French pharma spent $125 million upfront on the deal, which is worth up to $1 billion in biobucks – but DNL788 wasn’t one of the original compounds.
In 2020, Denali swapped out DNL747 for DNL788 after non-human primate studies of the former limited the firm’s confidence to conduct safe dose-escalation studies. DNL788, a backup compound at the time, was prioritised because early clinical and preclinical data suggested it had "superior drug properties." For more, see ViewPoints: Denali switches gears in neuroinflammation.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。